Clinicopathological characteristics of ypT0N0 urothelial carcinoma following neoadjuvant chemotherapy and cystectomy.


Journal

Journal of clinical pathology
ISSN: 1472-4146
Titre abrégé: J Clin Pathol
Pays: England
ID NLM: 0376601

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 25 01 2019
revised: 09 05 2019
accepted: 18 05 2019
pubmed: 6 6 2019
medline: 30 7 2019
entrez: 6 6 2019
Statut: ppublish

Résumé

To describe a large tertiary care academic centre's experience with patients who achieve a complete pathological response (ie, ypT0N0) following neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) with emphasis on morphological features present in the RC and clinical outcome. 41 patients with ypT0N0 disease following transurethral resection of bladder tumour (TURBT), NAC and RC with available clinical follow-up information were analysed. Slides from all RCs were reviewed to confirm pathological stage and assess for morphological parameters (eg, foreign body giant cell reaction, dystrophic calcification, scar and fat necrosis). With median follow-up of 32.8 months, the recurrence-free survival at 1 and 5 years was 97.4% and 93.5%, while the overall survival at 3 and 5 years was 94.2% and 88.6%, respectively. No patients died of urothelial carcinoma. Stage assigned at TURBT was 1 pTa (2%), 1 pT1 (2%), 38 pT2 (93%) and 1 pT3a (2%). 17 TURBTs demonstrated variant histology, with the majority of these being squamous (65%). The most common morphological features present at RC were scar (100%), foreign body giant cell reaction (80%), chronic inflammation within lamina propria (68%) and dystrophic calcifications (39%). Other morphological features were less common or absent. ypT0N0 disease at RC portends an excellent prognosis, regardless of stage or variant histology in the TURBT; scar, foreign body giant cell reaction, chronic inflammation and dystrophic calcifications are often present.

Identifiants

pubmed: 31164444
pii: jclinpath-2019-205742
doi: 10.1136/jclinpath-2019-205742
doi:

Types de publication

Journal Article

Langues

eng

Pagination

550-553

Informations de copyright

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Martin J Magers (MJ)

Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Hristos Z Kaimakliotis (HZ)

Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Marcelo P Barboza (MP)

Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Elhaam Bandali (E)

Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Nabil Adra (N)

Divisoin of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Michael O Koch (MO)

Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Liang Cheng (L)

Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA liang_cheng@yahoo.com.
Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH